Literature DB >> 33490233

miRNA-Based Feature Classifier Is Associated with Tumor Mutational Burden in Head and Neck Squamous Cell Carcinoma.

Yu Xia1, Qi Wang2, Xiaolin Huang3, Xinhai Yin4, Jukun Song4, Zhao Ke4, Xiaofeng Duan4.   

Abstract

Tumor mutation burden (TMB) is considered to be an independent genetic biomarker that can predict the tumor patient's response to immune checkpoint inhibitors (ICIs). Meanwhile, microRNA (miRNA) plays a key role in regulating the anticancer immune response. However, the correlation between miRNA expression patterns and TMB is not elucidated in HNSCC. In the HNSCC cohort of the TCGA dataset, miRNAs that were differentially expressed in high TMB and low TMB samples were screened. The least absolute contraction and selection operator (LASSO) method is used to construct a miRNA-based feature classifier to predict the TMB level in the training set. The test set is used to verify the classifier. The correlation between the miRNA-based classifier index and the expression of three immune checkpoints (PD1, PDL1, and CTLA4) was explored. We further perform functional enrichment analysis on the miRNA contained in the miRNA-based feature classifier. Twenty-five differentially expressed miRNAs are used to build miRNA-based feature classifiers to predict TMB levels. The accuracy of the 25-miRNA-based signature classifier is 0.822 in the training set, 0.702 in the test set, and 0.774 in the total set. The miRNA-based feature classifier index showed a low correlation with PD1 and PDL1, but no correlation with CTLA4. The enrichment analysis of these 25 miRNAs shows that they are involved in many immune-related biological processes and cancer-related pathways. The miRNA expression patterns are related to tumor mutation burden, and miRNA-based feature classifiers can be used as biomarkers to predict TMB levels in HNSCC.
Copyright © 2020 Yu Xia et al.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 33490233      PMCID: PMC7787755          DOI: 10.1155/2020/1686480

Source DB:  PubMed          Journal:  Biomed Res Int            Impact factor:   3.411


  48 in total

Review 1.  Liquid biopsy in the era of immuno-oncology: is it ready for prime-time use for cancer patients?

Authors:  P Hofman; S Heeke; C Alix-Panabières; K Pantel
Journal:  Ann Oncol       Date:  2019-09-01       Impact factor: 32.976

Review 2.  Methylation as a biomarker for head and neck cancer.

Authors:  L M R B Arantes; A C de Carvalho; M E Melendez; A L Carvalho; E M Goloni-Bertollo
Journal:  Oral Oncol       Date:  2014-03-20       Impact factor: 5.337

3.  Association of MUC16 Mutation With Tumor Mutation Load and Outcomes in Patients With Gastric Cancer.

Authors:  Xiangchun Li; Boris Pasche; Wei Zhang; Kexin Chen
Journal:  JAMA Oncol       Date:  2018-12-01       Impact factor: 31.777

Review 4.  Role of Immunotherapy in Head and Neck Cancer.

Authors:  Diane C Ling; Chris J Bakkenist; Robert L Ferris; David A Clump
Journal:  Semin Radiat Oncol       Date:  2018-01       Impact factor: 5.934

5.  limma powers differential expression analyses for RNA-sequencing and microarray studies.

Authors:  Matthew E Ritchie; Belinda Phipson; Di Wu; Yifang Hu; Charity W Law; Wei Shi; Gordon K Smyth
Journal:  Nucleic Acids Res       Date:  2015-01-20       Impact factor: 16.971

6.  Immunological differences between primary and metastatic breast cancer.

Authors:  B Szekely; V Bossuyt; X Li; V B Wali; G A Patwardhan; C Frederick; A Silber; T Park; M Harigopal; V Pelekanou; M Zhang; Q Yan; D L Rimm; G Bianchini; C Hatzis; L Pusztai
Journal:  Ann Oncol       Date:  2018-11-01       Impact factor: 32.976

7.  Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes.

Authors:  Yury O Nunez Lopez; Berta Victoria; Pawel Golusinski; Wojciech Golusinski; Michal M Masternak
Journal:  Rep Pract Oncol Radiother       Date:  2017-11-20

8.  DIANA-miRPath v3.0: deciphering microRNA function with experimental support.

Authors:  Ioannis S Vlachos; Konstantinos Zagganas; Maria D Paraskevopoulou; Georgios Georgakilas; Dimitra Karagkouni; Thanasis Vergoulis; Theodore Dalamagas; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2015-05-14       Impact factor: 16.971

Review 9.  Immunotherapy for Head and Neck Squamous Cell Carcinoma.

Authors:  Jessica Moskovitz; Jennifer Moy; Robert L Ferris
Journal:  Curr Oncol Rep       Date:  2018-03-03       Impact factor: 5.075

Review 10.  Molecular Drivers of Potential Immunotherapy Failure in Adrenocortical Carcinoma.

Authors:  Chiara Fiorentini; Salvatore Grisanti; Deborah Cosentini; Andrea Abate; Elisa Rossini; Alfredo Berruti; Sandra Sigala
Journal:  J Oncol       Date:  2019-04-01       Impact factor: 4.375

View more
  4 in total

1.  A Cell Component-Related Prognostic Signature for Head and Neck Squamous Cell Carcinoma Based on the Tumor Microenvironment.

Authors:  Siyu Li; Yajun Gu; Junguo Wang; Dengbin Ma; Xiaoyun Qian; Xia Gao
Journal:  Int J Genomics       Date:  2022-06-25       Impact factor: 2.758

2.  Comprehensive Analysis of RELL2 as a Potential Biomarker Associated with Tumor Immune Infiltrating Cells in a Pan-Cancer Analysis.

Authors:  Kadeerjiang Musha; Xinqi Ge; Nuraliya Ablikim; Bing Lu; Chen Chen; Jianfei Huang
Journal:  Dis Markers       Date:  2022-05-18       Impact factor: 3.464

3.  MiRNA-based model for predicting the TMB level in colon adenocarcinoma based on a LASSO logistic regression method.

Authors:  Zhengtian Li; Lingling Jiang; Rong Zhao; Jun Huang; Wenkang Yang; Zhenpei Wen; Bo Zhang; Gang Du
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

Review 4.  Targeting non-coding RNAs to overcome cancer therapy resistance.

Authors:  BaoQing Chen; Mihnea P Dragomir; Chen Yang; Qiaoqiao Li; David Horst; George A Calin
Journal:  Signal Transduct Target Ther       Date:  2022-04-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.